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Pigs are natural hosts for the same influenza virus subtypes as humans and are a valuable model for cross-protection
studies with influenza. In this study, we have used the pig model to examine the extent of virological protection
between a) the 2009 pandemic H1N1 (pH1N1) virus and three different European H1 swine influenza virus (SIV)
lineages, and b) these H1 viruses and a European H3N2 SIV. Pigs were inoculated intranasally with representative strains
of each virus lineage with 6- and 17-week intervals between H1 inoculations and between H1 and H3 inoculations,
respectively. Virus titers in nasal swabs and/or tissues of the respiratory tract were determined after each inoculation.
There was substantial though differing cross-protection between pH1N1 and other H1 viruses, which was directly
correlated with the relatedness in the viral hemagglutinin (HA) and neuraminidase (NA) proteins. Cross-protection
against H3N2 was almost complete in pigs with immunity against H1N2, but was weak in H1N1/pH1N1-immune pigs.
In conclusion, infection with a live, wild type influenza virus may offer substantial cross-lineage protection against
viruses of the same HA and/or NA subtype. True heterosubtypic protection, in contrast, appears to be minimal in
natural influenza virus hosts. We discuss our findings in the light of the zoonotic and pandemic risks of SIVs.Introduction
Swine influenza viruses (SIVs) are important for the swine
industry and as zoonotic agents. Moreover, they can lead
to the emergence of novel pandemic influenza viruses for
humans. In Europe, four lineages of SIV are enzootic in
swine populations. An H1N1 virus of wholly avian origin
became established in European swine in 1979 [1]. In the
mid 1980s, this H1N1 virus reassorted with descendants
of the 1968 Hong Kong human pandemic H3N2 virus
[2,3]. The resulting H3N2 SIV lineage has human-like
hemagglutinin (HA) and neuraminidase (NA) genes and
avian-like internal genes. The third lineage, H1N2, was
first reported in 1994, and is a reassortant virus that re-
tains most of the genome of the H3N2 SIV, but has ac-
quired an H1 gene from human seasonal viruses from
the 1980s [4,5]. The 2009 pandemic H1N1 (pH1N1)
virus is a reassortant with the NA and matrix (M)* Correspondence: kristien.vanreeth@ugent.be
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and the remaining genes from North American triple-
reassortant H1 SIVs [6]. The pH1N1 virus was first de-
tected in humans in April 2009 and only later in swine,
but it has become widespread in swine worldwide due
to large-scale reverse zoonotic transmissions [7]. Thus,
while all four SIV lineages have a distinct HA and/or
NA, the pH1N1 also has a different set of internal genes
compared to the three previously established SIVs. A
growing number of reassortants between these four line-
ages has been reported in recent years, especially between
pH1N1 and previously established SIVs [8].
The increasing number of H1 SIV lineages in Europe
and other continents, and the geographic differences in the
prevailing lineages have spurred interests in the extent of
cross-protection between them. Prior infection of pigs with
a European avian-like H1N1 SIV largely protects against
subsequent infection with the pH1N1 [9], or with a North
American triple-reassortant H1N1 SIV [10], despite the ab-
sence of cross-reactive serum hemagglutination-inhibitiondistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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known to what extent prior infection with pH1N1 offers
protection against the previously established European H1
SIVs. This question is also of public health concern as the
global spread of pH1N1 may generate cross-reactive im-
munity against some H1 SIVs in the human population,
making them less likely candidates for future pandemics.
Apart from cross-protection between variants of the
same HA subtype, cross-protection between viruses of
different HA subtypes (heterosubtypic protection) has
also been described. Heterosubtypic protection has been
repeatedly shown in rodents and ferrets [11-15], but only
rarely in natural hosts of influenza. In an experimental
pig infection study with European SIVs, only 1 out of 5
H1N1-immune pigs tested positive for the H3N2 chal-
lenge virus in oropharyngeal swabs, for 1 day only. How-
ever, challenge control pigs in that study also had minimal
virus titers in oropharyngeal swabs, and nasal swabs or tis-
sues of the respiratory tract were not examined [16]. Epi-
demiological data support the existence of heterosubtypic
immunity in humans that were exposed simultaneously or
consecutively to epidemic human seasonal H1N1 and
H3N2 viruses [17,18]. Also, the 1957 pandemic H2N2
virus appeared to have a lower disease incidence in adults
previously infected with an H1N1 virus [19]. Yet, the sig-
nificance and importance of heterosubtypic immunity in
natural influenza virus hosts remain unclear. In this study,
we sought to study cross-protection between a) pH1N1
and various H1 SIVs, and b) these distinct H1 SIVs and
H3N2. We use the pig as a natural host for SIVs and a
model for influenza in humans.Material and methods
Viruses and their genetic and antigenic relationships
Viruses for pig inoculation were propagated in embryo-
nated chicken eggs and used at the third or fourth pas-
sage. Their genetic constellations are shown in Figure 1.Figure 1 Genetic constellations of the five viruses used in this study.
polymerase acidic; HA, hemagglutinin; NP, nucleoprotein; NA, neuraminid
genes, which are derived from swine (M, NS and NP), human (PB1) and a
that is well conserved in North American swine influenza viruses.A/California/04/09 is a representative pH1N1, while sw/
Gent/28/10 (H1N1), sw/Gent/26/12 (H1N2) and sw/
Gent/172/08 (H3N2) are representative for SIVs that are
enzootic in Western Europe. Sw/Côtes d’Armor/0046/08
is an occasionally reported reassortant H1N1 (rH1N1) SIV
with the H1 derived from the European H1N2 SIV lineage
and the N1 from the European H1N1 lineage [20].
The sequences of the HA1 and NA segments of
the 5 viruses were available in GenBank (accession num-
bers FN646093, FN646099, KC142127, KC142128 and
KP406524-KP406529). The HA1 and NA segments were
compared at the amino acid level using the MEGALIGN
program (DNASTAR, Madison, WI, USA). Amino acid
differences at putative antigenic sites of the H1 and N2
proteins, as defined previously [21,22], were identified
by alignment using MEGA5 software [23]. Antigenic
characterization of the 5 viruses was performed by HI,
virus-neutralization (VN) and neuraminidase-inhibition
(NI) assays, using pig sera collected at 2 weeks after in-
oculation with each individual virus.Experimental design
Forty 6-week-old pigs from an influenza negative farm
were randomly assigned to 8 groups (n = 5) as shown in
Table 1. Each group was housed in a separate biosafety
level-2 HEPA-filtered isolation unit. All experiments were
authorized by the Ethical and Animal Welfare Committee
of the Faculty of Veterinary Medicine, Ghent University.
Virus inoculations of pigs were performed intranasally,
using 7.0 log10 50% egg infectious doses (EID50) of the re-
spective viruses in 3 mL (1.5 mL per nostril). Pigs were
unanesthetized and held in a vertical position with the
neck stretched. The inoculum was instilled into the mid-
dle nasal cavity by insertion of a 15-mm plastic cannula
attached to a 5-mL syringe.
The first experiment was designed to examine whether
infection immunity against pH1N1 offers protectionAbbreviations: PB2, polymerase basic 2; PB1, polymerase basic 1; PA,
ase; M, matrix; NS, nonstructural; TRIG, triple-reassortant internal
vian (PB2 and PA) influenza viruses forming a constellation of genes
Table 1 Experimental design
Viruses used for inoculation
Experiment 1 Experiment 2
Group 7 weeksa 13 weeksa 30 weeksa
A pH1N1 pH1N1 H3N2
B pH1N1 H1N1 H3N2
C pH1N1 rH1N1 -
D pH1N1 H1N2 H3N2
E PBS H1N1 H3N2
F PBS rH1N1 -
G PBS H1N2 H3N2
H PBS PBS H3N2
a The age of pigs at the time of virus inoculation.
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groups of pigs (A, B, C and D) were inoculated with
pH1N1 virus, and the remaining four groups (E, F, G
and H) were mock-inoculated with phosphate-buffered
saline (PBS). Six weeks later, the pH1N1-immune pigs
were inoculated with the same pH1N1 virus (group A), or
with 1 of 3 European H1 SIVs: H1N1 (group B), rH1N1
(group C), or H1N2 (group D). Three groups of influenza
naïve pigs served as H1N1 (group E), rH1N1 (group F), or
H1N2 (group G) challenge controls. Group H was inocu-
lated again with PBS. To determine virus excretion, nasal
swabs for virus titration were collected daily from all pigs
from 0–8 days post-primary inoculation and 0–7 days
post-secondary inoculation. Blood samples for serology
were collected at 0 and 14 days post-primary inoculation,
and at 0, 5, 7, 10 and 14 days post-secondary inoculation.
The second experiment aimed at studying the hetero-
subtypic protection between H1 and H3 viruses (Table 1).
Six groups from the first experiment (A, B, D, E, G and H)
were inoculated with H3N2, 17 weeks after the secondary
inoculation. Nasal swabs for virus titration were collected
daily from all pigs from 0–7 days post-tertiary inoculation,
or until euthanasia. Two pigs per group were euthanized
at 4 days post-tertiary inoculation to examine virus titers
of the entire respiratory tract: nasal mucosa respiratory
and olfactory regions, tonsil, trachea, apical, cardiac, andTable 2 Percent identity of the amino acid sequences of viral h
Virus A/California/04/09 Sw/Gent/28/10
HA1 NA HA1 NA
A/California/04/09 (pH1N1) 100 100
Sw/Gent/28/10 (H1N1) 73 91 100 100
Sw/Côtes d’Armor/0046/08 (rH1N1) 72 91 70 97
Sw/Gent/26/12 (H1N2) 71 41 69 40
Sw/Gent/172/08 (H3N2) 34 42 35 40diaphragmatic lobes of the left and right lungs, and the
accessory lung lobe. Each tissue sample was collected and
titrated separately. Blood samples for serology were col-
lected at 0 and 14 days post-tertiary inoculation.Virus titration
Sterile nasal swabs (Copan 160C, Copan Italia S.p.A.) were
weighed before and after collection to determine virus ti-
ters per 100 mg nasal secretions. Swabs from both nostrils
were suspended in 1 mL sterile PBS supplemented with
antibiotics. Tissues were weighed and homogenized in ster-
ile PBS with antibiotics to obtain 20% (w/v) homogenates.
Nasal swab specimens and tissue homogenates were ti-
trated in Madin-Darby canine kidney (MDCK) cells by the
50% tissue culture infectious doses (TCID50) assay as de-
scribed elsewhere [24].Serological assays
Serum antibody responses were examined in HI, VN and
NI assays, as described elsewhere [25,26]. All sera col-
lected before and at 2 weeks after each inoculation were
examined against all 5 viruses in all 3 assays. At 5, 7, 10
and 14 days post-secondary inoculation, additional VN as-
says against the respective challenge H1 viruses were per-
formed. Antibody titers were expressed as the reciprocal
of the highest serum dilution that showed complete inhib-
ition of HA of 4 hemagglutinating units of virus (HI
assay), 50% neutralization of 100 TCID50 of virus in
MDCK cells (VN assay), or 50% reduction of NA activity
(NI assay). Starting dilutions were 1:2 in the VN assay, and
1:10 in HI and NI assays.Statistics
Nasal virus shedding in each group was quantified by calcu-
lation of the area under the curve (AUC). Mann–Whitney
tests were used to compare antibody levels between any
two experimental groups, and before and after inocula-
tion in each group. Differences were considered signifi-
cant when p < 0.05. GraphPad Prism5 software (GraphPad
Software, San Diego, CA, USA) was used for all statistical
analyses.emagglutinin (HA1) and neuraminidase (NA) segments
Sw/Côtes d’Armor/0046/08 Sw/Gent/26/12 Sw/Gent/172/08
HA1 NA HA1 NA HA1 NA
100 100
90 40 100 100
32 39 33 84 100 100
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Genetic and antigenic relationships between pH1N1 and
European SIVs
Genetic relationships between viruses were assessed by
comparison of the homology in viral HA1 and NA amino
acid sequences (Table 2). Antigenic relationships between
viruses were examined in cross-HI, VN and NI assays,
using monospecific pig sera (Table 3). The rH1N1 and
H1N2 viruses showed 90% amino acid sequence identity
in their HA1 segments and cross-reactivity in HI and VN
assays, reflecting the same human-like HA lineage of the
two viruses. The HA1 segments of H1N1, rH1N1 and
H1N2 had a similar homology (71-73%) to the classical
H1 of pH1N1. Alignment of HA1 antigenic sites of
pH1N1 with those of H1N1, rH1N1 and H1N2 re-
vealed 17, 26 and 27 amino acid differences, respectively
(Additional file 1). Cross-reactivity between pH1N1 and
other European H1 SIVs was absent in the HI assay, and
rare in the VN assay. H3N2 failed to cross-react with any
H1 viruses in HI and VN assays.
The H1N1 and rH1N1 showed 97% amino acid identity
in their NAs, which were closely related to the NA of
pH1N1 (91% identity), reflecting the same avian-like N1
lineage of the three viruses. Unfortunately, the complete
antigenic sites on N1 neuraminidase have not been de-
fined yet. The human-like NAs of H1N2 and H3N2 had
84% amino acid identity and 10 residue differences in anti-
genic sites (Additional file 2). Consistent with the genetic
relatedness, cross-reactivity in the NI assay was ob-
served between viruses of the same avian-like N1 or
human-like N2 lineage.
Experiment 1: protection against challenge with various
European H1 SIVs in pigs with infection immunity against
pH1N1
After primary inoculation with pH1N1, pigs from groups
A, B, C and D had similar mean AUC values (range from
24.9-27.4) and nasal shedding during 6–7 days. The mock-
inoculated pigs tested negative for virus at all time points.Table 3 Geometric mean antibody titers in hemagglutination-in
inhibition (NI) assays at 14 days post-inoculation of pigs with v
Antibody titer against
Virus for inoculation No. of pigs A/California/04/09 Sw/Gent/28/
HI VN NI HI VN N
A/California/04/09 (pH1N1) 20 89 76 109 <10 3 1
Sw/Gent/28/10 (H1N1) 5 <10 3 16 80 384 3
Sw/Côtes d’Armor/0046/08
(rH1N1)
5 <10 2 30 <10 <2 4
Sw/Gent/26/12 (H1N2) 5 <10 <2 <10 <10 <2 <
Sw/Gent/172/08 (H3N2) 3 <10 <2 <10 <10 <2 <
The detection limits were 1:2 in the VN assay, and 1:10 in HI and NI assays. Negativ
calculation of geometric mean antibody titers. Values in bold are titers against theFigure 2A shows mean virus titers in nasal swabs post-
secondary inoculation with pH1N1, H1N1, rH1N1 or
H1N2. The respective challenge control groups (E, F and
G) excreted high titers of the challenge viruses for 5–6 days
(mean AUC= 23.7, 25.1 and 23.6, respectively). In contrast,
pH1N1-immune pigs showed complete protection (AUC=
0) against challenge with the homologous virus (group A)
or with H1N1 (group B), and nearly complete protection
against challenge with rH1N1 (group C) (mean AUC= 0.1).
Virus excretion was detectable in 3 out of 5 pigs from
group C, for 1 day only and at minimal virus titers. A
slightly weaker protection was observed after challenge
with H1N2 (group D): 4 out of 5 pigs had virus shed-
ding for 1–3 days (mean AUC = 2.1).
Prior to the start of the experiment, pigs were sero-
negative against all tested influenza viruses in HI, VN
and NI assays. At 2 weeks post-primary inoculation with
pH1N1, pigs from groups A, B, C and D had similar
antibody titers (p > 0.05) against the homologous virus in
all assays. The geometric mean titers (GMTs) are shown
in Table 3. At 6 weeks post-primary inoculation (time of
the secondary inoculation with various H1 viruses), the HI,
VN and NI GMTs against pH1N1 were 39, 106 and 260,
respectively. Cross-reactive antibodies against H1N1,
rH1N1 and H1N2 were undetectable in all pH1N1-
immune pigs in the HI assay, but most pigs had low cross-
reactive VN titers. Higher cross-reactive NI titers were de-
tected against H1N1 (GMT 36) than against rH1N1 (GMT
17) (p < 0.05). The challenge control pigs (groups E, F and
G) remained seronegative before the secondary inoculation,
but had developed HI, VN and NI antibodies against the
respective challenge virus at 14 days post-secondary inocu-
lation (Table 3). Figure 2B illustrates the more rapid devel-
opment of VN antibodies against the challenge virus in
challenge control pigs than in pH1N1-immune pigs. Anti-
pH1N1 antibody titers remained at pre-challenge levels in
group A, B and C in all assays (p > 0.05), but increased sig-
nificantly in group D in HI and VN assays (p < 0.05)
(Additional file 3).hibition (HI), virus-neutralization (VN), and neuraminidase-
arious influenza viruses.
10 Sw/Côtes d’Armor/0046/08 Sw/Gent/26/12 Sw/Gent/172/08
I HI VN NI HI VN NI HI VN NI
6 <10 9 22 <10 4 <10 <10 <2 <10
20 <10 3 40 <10 4 <10 <10 <2 <10
0 70 795 211 20 262 <10 <10 <2 <10
10 15 114 <10 127 1276 46 <10 <2 15
10 <10 <2 <10 <10 <2 12 160 347 381
e samples were assigned a value of half the minimum detectable titer for the
homologous virus.
Figure 2 Virus titers in nasal swabs (A) and virus-neutralizing (VN) antibody titers in serum (B) post-secondary inoculation with various
H1 viruses. Nasal swabs were collected daily from day 0 to 7 post-secondary inoculation to determine virus titers per 100 mg nasal secretions.
VN antibody titers were determined against the respective challenge H1 virus on days 0, 5, 7, 10 and 14 post-secondary inoculation. Horizontal
dotted lines represent the detection limit of the assay: 1.7 log10 TCID50 for virus titration, 2 for the VN assay. *p < 0.05 and **p < 0.01, by the
Mann–Whitney test.
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European H3N2 SIV in pigs with infection immunity
against various H1 virus(es)
Figure 3A shows mean virus titers in nasal swabs post-
tertiary inoculation with a European H3N2 SIV. All chal-
lenge control pigs (group H), pigs immune to pH1N1
(group A) or pH1N1 followed by H1N1 (group B) shed
high titers of virus for 4–6 days (mean AUC= 23.2, 18.9
or 16.4, respectively). All H1N1-immune pigs (group E)
also shed viruses for at least 2–6 days, but the virus titers
were reduced (mean AUC= 12.3). Only one pig with in-
fection immunity against H1N2 (group G) and two pigs
with infection immunity against both pH1N1 and H1N2
(group D) had detectable virus excretion (mean AUC=
0.14 and 1.65, respectively). Figure 3B shows individual
virus titers in the respiratory tract of 2 pigs of each group
at 4 days post-tertiary inoculation. Challenge control pigs
(group H) were virus-positive in all tissues, except for the
olfactory region of the nasal mucosa of one pig. Virus iso-
lation rates and virus titers in the other groups reflected
those in nasal swabs. Pigs immune to pH1N1 (group A)
or both pH1N1 and H1N1 (group B) showed only a min-
imal reduction of virus replication. A higher reduction of
virus titers was observed in the pigs immune to H1N1
alone (group E), while those immune to H1N2 alone
(group G) or pH1N1 followed by H1N2 (group D) were
almost completely protected against H3N2 replication.
All pigs lacked HI and VN antibodies against H3N2 be-
fore the tertiary inoculation. Cross-NI antibodies against
H3N2 were only detected in pigs previously exposed to
H1N2, and titers were higher in group G (GMT 70) than
in group D (GMT 17) (p < 0.05). At 14 days post-tertiary
inoculation with H3N2, all pigs developed antibodies or
showed an increase in pre-existing antibody titers
against H3N2 (Table 4). Antibody titers against H1 vi-
ruses remained at pre-challenge level in all assays (p > 0.05).
Discussion
We have shown nearly complete cross-protection against
replication of European H1 SIV lineages in pigs with infec-
tion immunity against pH1N1, but only a weak cross-
protection against the H3N2 subtype in pigs with infection
immunity against various H1N1 viruses. In line with previ-
ous studies [9,27], all three H1 SIVs used in our studies
failed to cross-react with pH1N1 in HI assays with post-
infection swine sera, and there was minimal cross-reactivity
in VN assays. The VN assay is known to be more sensitive
than the HI assay, and the former assay does not only de-
tect antibodies that inhibit the attachment of the virus to
target cells, but also antibodies that can block the fusion of
the viral and endosomal membranes [28]. Cross-HI assays
with high-titered hyperimmune swine sera have also shown
low levels of cross-reactivity between pH1N1 and European
avian-like H1N1 but not human-like H1N2 SIVs [27]. TheHA1 of the European H1 SIVs had similar low percentages
(69-71%) of amino acid homology to pH1N1. However, a
detailed analysis of the antigenic sites revealed fewer amino
acid differences between the classical H1 of pH1N1 and the
avian-like H1 of H1N1 as compared to the human-like H1
of rH1N1 and H1N2 SIVs. Interestingly, the Sa (13 amino
acids) site is an immunodominant antigenic site [29-31],
and was found to be completely conserved between the
first two viruses as previously reported [32], while there
were 5–6 amino acid differences between pH1N1 and the
human-like H1 SIVs. This may explain why the pH1N1-
immune pigs in our study were best protected against the
avian-like H1N1 SIV. A complete cross-protection against
the pH1N1 after prior infection of pigs with the avian-like
H1N1 SIV has been demonstrated in a previous study [9].
Likewise, prior infection or vaccination with a 1918 pan-
demic or classical swine H1N1 virus, which differ from
pH1N1 in only 1 amino acid in the Sa antigenic site, re-
sulted in nearly complete protection from the latter virus in
mice and ferrets [33-35]. Furthermore, there is strong
evidence for cross-protection between pH1N1 and his-
torical human seasonal H1N1 viruses from the 1930-
40s in humans and in experimental animal models
[34,36,37]. Yet, these viruses have only 67-76% amino
acid homologies in their HA1 and as many as 5 amino
acid differences in the Sa antigenic site [34]. Some of
the viruses used for prior infection and challenge in the
present study also have NAs of the same lineage. This
was the case for pH1N1 and European SIVs of the H1N1
subtype (H1N1 and rH1N1), as well as for the European
H1N2 and H3N2 SIVs. Unlike antibodies against HA, anti-
NA antibodies cannot neutralize influenza viruses, but they
do play a significant secondary role in protection against
influenza in humans and animals [38-41]. Therefore, it is
not surprising that pH1N1-immune pigs were better pro-
tected against European H1N1 than H1N2 SIVs, and that
H1N2-immune pigs were better protected against H3N2
challenge than H1N1-immune pigs.
Protection between viruses of H1N1 and H3N2 subtype
was clearly less robust than that between viruses of the
same HA and/or NA subtype. Yet, pigs with infection im-
munity against the avian-like H1N1 SIV were better pro-
tected against H3N2 than pH1N1-immune pigs. This
suggests a contribution of immune responses against in-
ternal proteins, which are shared between avian-like H1N1
and human-like H3N2 SIVs but are of different origins in
pH1N1, except for the M protein. In pigs that had been
subsequently exposed to pH1N1 and the avian-like H1N1,
protection against H3N2 was similar to that in pigs ex-
posed twice to pH1N1, and inferior to that in pigs exposed
to H1N1 alone. This is most likely due to the failure of the
H1N1 virus to replicate and induce specific immune re-
sponses in pH1N1-immune pigs, as indicated by the nasal
virus titers and serological responses. Our data are largely
Figure 3 Virus titers in nasal swabs (A) and respiratory tissues (B) post-tertiary inoculation with H3N2. Nasal swabs were collected daily
from day 0 to 7 post-tertiary inoculation to determine virus titers per 100 mg nasal secretions. Two pigs per group were euthanized at day 4
post-tertiary inoculation to determine virus titers in 1 g respiratory tissues. Horizontal dotted lines represent the detection limit for virus titration: 1.7
log10 TCID50.
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Table 4 Geometric mean antibody titers against the H3N2
virus in hemagglutination-inhibition (HI), virus-neutralization
(VN), and neuraminidase-inhibition (NI) assays at 14 days
post-tertiary inoculation with H3N2
Group Virus inoculations HI VN NI
A pH1N1-6w-pH1N1-17w-H3N2 202 116 320
B pH1N1-6w-H1N1-17w-H3N2 254 266 254
D pH1N1-6w-H1N2-17w-H3N2 16 26 320
E Mock-6w-H1N1-17w-H3N2 127 185 320
G Mock-6w-H1N2-17w-H3N2 20 16 320
H Mock-6w-mock-17w-H3N2 160 347 381
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tection in pigs, ferrets, and mice [11,13-16,42], none of
which showed a complete protection between H1 and H3
viruses. For example, prior infection of ferrets with pH1N1
or a seasonal H1N1 virus resulted in a shorter duration of
nasal excretion of seasonal H3N2 virus, i.e. 5 days instead
of 7 days in unprimed influenza naïve ferrets [13,15]. In
mice, prior infection with H1N1 or pH1N1 did not reduce
H3N2 virus titers in the lungs at 4 days post-challenge, but
titers were undetectable or reduced by 104-fold at 7 days
post-challenge [11,42].
Although heterosubtypic protection has been frequently
studied in mice, the pig model has some specific advan-
tages for studying protection between influenza viruses.
Pigs are natural hosts for a variety of genetically and anti-
genically diverse H1 and H3 viruses. Most SIVs have an
HA derived from viruses that once circulated in humans
and the pH1N1 is a shared virus between humans and
swine [43]. Nearly all SIVs are natural reassortants. As a
result, the SIVs used in this study share one to seven genes
with each other, and this allows examination of the rela-
tive importance of the corresponding proteins for protec-
tion. As pointed out before [44-46], the pathogenesis of
influenza is very similar in pigs and in humans, and there
are also striking similarities in their immune responses. In
mice, the outcome of infection experiments depends on
the mouse and virus strain used. For instance, upon infec-
tion with PR/8, DBA/2 mice showed a greater susceptibil-
ity to infection, more rapid weight loss and death, elevated
cytokine production, and more severe lung histopathology
than C57BL/6 mice [47]. Also, human influenza viruses
generally require adaptation to be able to replicate and
achieve virulence in mice, and the adapted virus may be
antigenically and phenotypically very different from the
initial strain [48]. Finally, mice transmit influenza viruses
inefficiently and nasal virus excretion cannot be evaluated
in mice [49]. Pigs, in contrast, are highly susceptible to a
variety of human H1 and H3 viruses [24,50,51]. And un-
like mice, pigs can shed high titers of virus in nasal swabs
for 4–6 days.During the last few years, there have been several sero-
logic investigations for cross-reactive antibodies against
European H1 and H3 SIVs in humans of different age
categories [52-54]. HI antibodies against the European
H3N2 SIV were present in 70% of those born before
1990, but were rare in the younger population [54]. In
comparison, HI antibodies against the European avian-
like H1N1 SIV were detected in only approximately 10% of
humans in 2009, and they showed only a minimal in-
crease in humans with seroconversion to pH1N1
[53,55,56]. This is in agreement with our finding that
pH1N1 infection did not induce detectable serum HI
antibodies against the avian-like H1N1 SIV. On the
other hand, pH1N1-immune pigs showed a complete
virological protection against the avian-like H1N1 SIV.
This further supports the notion that infection with a
live influenza virus can induce cross-protection in the
absence of cross-reactive serum HI antibodies and ar-
gues for more in vivo cross-protection studies in animal
models. From such studies, we conclude that humans, es-
pecially the young population born after 1990, will likely
have better immune protection against European H1 than
H3 SIVs. This is based on the presence of minimal protec-
tion against European H3N2 SIVs in pigs with infection im-
munity against contemporary human H3N2 viruses [24] or
pH1N1, whereas infection immunity against pH1N1 seems
to offer significant protection against the major H1 SIVs.
In conclusion, our study shows that infection with a
live, wild type influenza virus may offer substantial cross-
lineage protection against viruses of the same HA and/or
NA subtype. Heterosubtypic protection between viruses of
different HA and NA subtypes, in contrast, appears to be
weak in pigs. Because they are natural hosts for the same
influenza virus subtypes as humans, pigs have some
unique advantages as a model for cross-protection
studies with influenza. According to our data, the glo-
bal spread of pH1N1 in humans will enhance their
cross-protective immunity against European H1 SIVs,
making those viruses less likely to cause pandemics in
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